| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882912 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 25 Pages |
Abstract
Coltuximab ravtansine was well tolerated but was associated with a low clinical response rate in patients with relapsed or refractory ALL.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Hagop M. Kantarjian, Bruno Lioure, Stella K. Kim, Ehab Atallah, Thibaut Leguay, Kevin Kelly, Jean-Pierre Marolleau, Martine Escoffre-Barbe, Xavier G. Thomas, Jorge Cortes, Elias Jabbour, Susan O'Brien, Pierre Bories, Corina Oprea, Laurence Hatteville,